Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Bone|October 22, 2020
Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney diseaseSyazrah Salam, Orla Gallagher, Fatma Gossiel, et al.
Journal of the American Society of Nephrology : JASN|March 21, 2018
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal OsteodystrophySyazrah Salam, Orla Gallagher, Fatma Gossiel, et al.
Kidney International|July 15, 2005
The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acidArif Khwaja, Claire C Sharpe, Mazhar Noor, et al.
Journal of Cellular Biochemistry|September 28, 2005
Prenylation is not necessary for endogenous Ras activation in non-malignant cellsArif Khwaja, Mark E C Dockrell, Bruce M Hendry, et al.
Nephron. Clinical Practice|December 3, 2011
Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of responseAnderson Roman Gonçalves, Arif Khwaja, Aimun K Ahmed, et al.
Journal of the American Society of Nephrology : JASN|March 28, 2003
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritisHelen C Clarke, Hemant M Kocher, Arif Khwaja, et al.
Kidney International Reports|August 7, 2023
PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous NephropathyOmar Ragy, Sebastian Bate, Samar Bukhari, et al.
The New England Journal of Medicine|November 3, 2022
Renin-Angiotensin System Inhibition in Advanced Chronic Kidney DiseaseSunil Bhandari, Samir Mehta, Arif Khwaja, et al.
Kidney International Reports|July 9, 2025
Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous NephropathyPatrick Hamilton, Sebastian Bate, Omar Ragy, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 3, 2015
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trialSunil Bhandari, Natalie Ives, Elizabeth A Brettell, et al.
Pageof 3